Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma
NCT04248387
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Melanoma Stage IIIB-IV
Interventions
DRUG:
Toripalimab
Sponsor
Fudan University